Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
NK cell therapy is a form of immunotherapy that utilizes the body’s own Natural Killer (NK) cells to help fight abnormal cells, such as cancer cells. A central question many people have is why this process involves taking their cells out of their body, culturing them in a lab, and then returning them. This article explains the scientific rationale behind the *ex vivo* (outside the body) activation and expansion process and why it is a fundamental part of this therapeutic approach.
The Goal of Ex Vivo NK Cell Expansion: Number and Potency
The primary objective of culturing NK cells outside the body is twofold: to significantly increase their numbers and to enhance their cytotoxic (cell-killing) activity. NK cells are the immune system’s first line of defense, capable of identifying and destroying abnormal cells without prior sensitization. However, the effectiveness of this natural surveillance can diminish. Factors like aging, chronic stress, and the progression of diseases can lead to a decline in both the quantity and the functional capacity of circulating NK cells. The *ex vivo* expansion process is designed to overcome these limitations by creating a large, highly active population of a patient’s own NK cells, which are then reintroduced into the body to bolster its natural defenses.
Why Simple Reinfusion Isn’t Enough: Overcoming In-Body Limitations
While our bodies naturally produce NK cells, the environment within a person dealing with a chronic illness or cancer can be challenging for the immune system. Cancer cells, for example, can develop mechanisms to evade or suppress immune cells, rendering the existing NK cells less effective. Furthermore, the number of naturally circulating NK cells may not be sufficient to mount a powerful response against a large number of abnormal cells.
By removing the NK cells from this suppressive environment, a specialized laboratory can provide ideal conditions for their growth and activation. This controlled setting allows for a process of stimulation and proliferation that would be difficult to achieve within the body itself. The goal is to return a force of NK cells that is not only greater in number but also functionally superior to the cells that were initially collected.
A Step-by-Step Look at the NK Cell Culture Process
The journey of your NK cells from collection to reinfusion is a precise, multi-step process conducted in a highly specialized environment. While specific protocols may vary, the general workflow is as follows:
- Blood Collection: The process begins with a standard blood draw, similar to what you would experience during a routine health check. A sufficient volume of peripheral blood is collected to isolate the immune cells.
- Cell Isolation: The collected blood is sent to a dedicated Cell Processing Facility (CPF). Here, technicians use advanced laboratory techniques to separate the NK cells from other blood components like red blood cells and platelets.
- Activation: Once isolated, the NK cells are stimulated using specific signaling molecules, such as cytokines. This step acts as a ‘wake-up call,’ priming the cells and enhancing their natural ability to recognize and attack target cells.
- Expansion (Culture): The activated NK cells are placed in a sterile, nutrient-rich culture medium. Over a period of approximately two to three weeks, they are carefully nurtured to encourage them to multiply, often resulting in a population that is many times larger than the original number.
- Quality Control and Harvest: Before the cells are cleared for use, they undergo rigorous quality checks to ensure their purity, viability, and safety. Once they pass these tests, the expanded and activated NK cells are harvested and prepared for infusion.
- Infusion: The final cell product is returned to the patient’s body through a simple intravenous (IV) drip at the clinic.
Safety, Regulation, and Considerations in Japan
In Japan, cell therapies like NK cell therapy are provided under a strict regulatory framework. The entire culturing process must take place in a Cell Processing Facility that complies with national standards. Furthermore, treatments are offered in accordance with the Act on the Safety of Regenerative Medicine, which is overseen by Japan’s Ministry of Health, Labour and Welfare. This ensures that the procedures for cell processing, quality management, and patient safety are clearly defined and followed.
It is important to understand that NK cell therapy is considered an elective treatment and is not covered by Japanese public health insurance. This therapy is not intended to replace standard cancer treatments such as surgery, chemotherapy, or radiation therapy. In some cases, it may be used in combination with these conventional therapies, but this must be determined based on a physician’s comprehensive evaluation of the individual’s condition.
What to Discuss with Your Doctor Beforehand
The decision to pursue any medical treatment requires careful consideration and a thorough discussion with a qualified physician. Before considering NK cell therapy, it is essential to have a consultation to determine if you are a suitable candidate. During this consultation, the doctor will explain the entire process, including the potential benefits and limitations. Key topics to cover include:
- Your specific medical condition and treatment history.
- The expected treatment schedule, including the number and frequency of infusions.
- Potential risks and side effects, which may include temporary fever or fatigue after the infusion.
- The total cost of the treatment plan.
At Grand Green Osaka Umekita Clinic, located in the Umeda area of Osaka, our physicians provide detailed consultations for those interested in learning more about this option. For a general overview of the treatment flow and features, please review our dedicated page on NK Cell Therapy, which is available in multiple languages.
Summary: A Controlled Boost for Your Immune System
The process of expanding NK cells outside the body is a cornerstone of this immunotherapy approach. It is a calculated strategy to amplify the body’s own defense mechanisms in a controlled, scientific manner. By isolating, activating, and multiplying a patient’s NK cells in a specialized facility, the therapy aims to return a more numerous and more potent immune force to the body. As with any advanced medical treatment, a comprehensive consultation with a doctor is the essential first step to understanding if this approach is appropriate for your individual circumstances.
- 11. Blood CollectionA standard blood draw from the patient
- 22. Cell Culture & ActivationIncrease number and potency in a lab
- 33. Quality ControlEnsure cell purity, viability, and safety
- 44. InfusionReturn the enhanced cells via IV drip
This diagram is a conceptual summary of the process described in this article
References
- PubMed: Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis. (2023)
- PubMed: Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy. (2017)
- PubMed: Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy. (2013)
- PubMed: Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. (2019)
- PubMed: Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. (2014)
- PMC: Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production. (2023)
- PMC: Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo. (2023)
- PMC: Mucosal-associated invariant T cells for cancer immunotherapy. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.